By studying the effects of immune cells that surround blood vessels in the brain, Weill Cornell Medicine researchers have discovered a new pathway involving these cells that may contribute to the cause of Alzheimer’s disease.

For their study, published May 17 in the journal Circulation Research, the researchers sought to determine which cells in the brain were responsible for producing the reactive oxygen species (ROS).

“These free radicals are nasty molecules that paralyze the vessels so that they can’t function normally. As a result, brain cells are deprived of the blood supply of oxygen and glucose they need to function properly,” said senior study author Dr. Costantino Iadecola, director of the Feil Family Brain and Mind Research Institute and the Anne Parrish Titzell Professor of Neurology at Weill Cornell Medicine.

In their study, the investigators examined cells in the brain called perivascular macrophages (PVM), which surround blood vessels and pick up and remove damaging metabolic byproducts floating around the brain. The team focused on these cells because amyloid–beta tends to accumulate in the vascular space where PVM are located.

“We saw that when cells are exposed to amyloid beta, these PVM start producing free radicals like crazy,” Dr. Iadecola said.

To determine whether the PVM were involved in the ROS production, the researchers removed PVM by injecting into the brains of mice spherical lipid droplets called liposomes that contained the drug clodronate.

“The liposomes acted as a kind of Trojan horse,” said Dr. Laibaik Park, assistant professor of research in neuroscience in the Feil Family Brain and Mind Research Institute, and first author of the study. “The PVM digest the lipids and sets the drug loose into the cell, forcing them to die.”

Drs. Park and Iadecola administered the liposomes in mice with Alzheimer’s disease; ROS paralyzed the blood vessels in the rodents. Remarkably, the team found that the blood vessels in these mice appeared to work normally once rid of PVM, despite the presence of amyloid–beta. “This showed that without the PVM, amyloid–beta was unable to exert its damaging effects on brain blood vessels,” Dr. Park said.

The researchers then sought to learn what caused the PVM to produce ROS. Previous studies showed that macrophages have innate immune receptors on their surface called CD36 that help them bind and interact with other immune cells and proteins. The next step was to determine what happens when CD36 was not present, Dr. Iadecola said.

To remove the CD36 receptors from PVM, the researchers first used radiation to destroy the PVM. Then, old PVM were replaced through a bone marrow transplant with new PVM that did not have the receptor.

“When we did that, it was as good as getting rid of the whole macrophage, proving that the presence of CD36 on PVM was necessary for the ROS production and vascular damage to occur,” Dr. Iadecola said.

The researchers ultimately discovered that when amyloid beta binds to the CD36 receptor of PVM, a signaling pathway is triggered, which causes an enzyme called NADPH oxidase, to produce free radicals.

Researchers will now seek to develop methods that block CD36 or NADPH oxidase in the cells, which may reduce the amount of amyloid–beta in the brain and potentially slow down the progression of Alzheimer’s disease. “Delaying the process may give you more years with a healthy mind,” Dr. Iadecola said.

He also added that the maintenance of blood vessel health is crucial for a wide variety of brain diseases. “Our research shows that even in a disease that doesn’t start with a blood vessel, by making the vessels work better, there may be a beneficial effect,” Dr. Iadecola said.